Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Intellia Therapeutics (NASDAQ:NTLA) announced on October 1, 2025 inducement equity awards to six new employees under its 2024 Inducement Plan. The grants total 65,200 RSUs of common stock, vesting one‑third on Oct 1, 2026, 2027 and 2028, subject to continued service. The awards were granted outside Intellia’s stockholder‑approved plans and were approved by the compensation committee as a material inducement to employment in accordance with Nasdaq Listing Rule 5635(c)(4). The 2024 Inducement Plan was adopted by the board in June 2024. No cash amounts, price terms, or pro forma share dilution metrics were included in the release.
Intellia Therapeutics (NASDAQ:NTLA) ha annunciato il 1 ottobre 2025 indennità azionarie di incentivazione per sei nuovi dipendenti secondo il Piano di Induzione 2024. Le assegnazioni ammontano a 65.200 RSU di azioni ordinarie, che vestono in tre parti: un terzo il 1 ottobre 2026, nel 2027 e nel 2028, soggette a continuativa prestazione. Le assegnazioni sono state concesse al di fuori dei piani approvati dagli azionisti di Intellia e sono state approvate dal comitato di compensazione come incentivo sostanziale all'occupazione in conformità con la Nasdaq Listing Rule 5635(c)(4). Il Piano di Induzione 2024 è stato adottato dal consiglio nel giugno 2024. Nel comunicato non sono stati inclusi importi in contanti, termini di prezzo o metriche di diluizione pro forma.
Intellia Therapeutics (NASDAQ:NTLA) anunció el 1 de octubre de 2025 concesiones de indemnización de acciones para seis nuevos empleados bajo su Plan de Inducción 2024. Las adjudicaciones totalizan 65,200 RSU de acciones ordinarias, con vesting de un tercio el 1 de octubre de 2026, 2027 y 2028, sujeto a continuación del servicio. Las adjudicaciones se concedieron fuera de los planes aprobados por los accionistas de Intellia y fueron aprobadas por el comité de compensación como un incentivo material para el empleo de conformidad con la Regla 5635(c)(4) de Nasdaq Listing. El Plan de Inducción 2024 fue adoptado por la junta en junio de 2024. El comunicado no incluyó montos en efectivo, términos de precio ni métricas de dilución pro forma.
Intellia Therapeutics (NASDAQ:NTLA)은 2025년 10월 1일에 2024 Inducement Plan에 따른 여섯 명의 신규 직원에게 보상 유인 주식 부여를 발표했습니다. 보상은 총 65,200 RSU의 보통주로, 2026년 10월 1일, 2027년, 2028년에 각각 1/3씩 vesting되며 지속 근무에 따라 다릅니다. 이 상여는 Intellia의 주주 승인 계획 외부에서 부여되었으며, 보상위원회가 Nasdaq Listing Rule 5635(c)(4)에 따라 고용에 대한 실질적 유인으로 승인했습니다. 2024 Inducement Plan은 이사회가 2024년 6월에 채택했습니다. 발표에는 현금 금액, 가격 조건 또는 프로 포르마 주식 희석 지표가 포함되지 않았습니다.
Intellia Therapeutics (NASDAQ:NTLA) a annoncé le 1 octobre 2025 des attributions d’actions d’induction à six nouveaux employés dans le cadre de son Plan d’induction 2024. Les attributions totalisent 65 200 RSU d’actions ordinaires, vesting d’un tiers le 1 octobre 2026, puis en 2027 et 2028, sous réserve de la poursuite du service. Les attributions ont été accordées en dehors des plans approuvés par les actionnaires d’Intellia et ont été approuvées par le comité de rémunération comme incitation matérielle à l’emploi conformément à la Règle Nasdaq 5635(c)(4). Le Plan d’induction 2024 a été adopté par le conseil en juin 2024. Aucun montant en espèces, termes de prix ou métriques de dilution pro forma n’étaient inclus dans le communiqué.
Intellia Therapeutics (NASDAQ:NTLA) gab am 1. Oktober 2025 Anreiz-Aktienzuteilungen an sechs neue Mitarbeiter im Rahmen ihres 2024 Inducement Plan bekannt. Die Zuwendungen belaufen sich auf insgesamt 65.200 RSU Stammaktien, die in drei gleiche Tranchen vesten: am 1. Oktober 2026, 2027 und 2028, vorbehaltlich fortgesetzter Dienstzeit. Die Zuwendungen wurden außerhalb der von den Aktionären genehmigten Plänen von Intellia gewährt und vom Vergütungsausschuss als wesentlicher Anreiz für eine Anstellung gemäß der Nasdaq Listing Rule 5635(c)(4) genehmigt. Der 2024 Inducement Plan wurde vom Vorstand im Juni 2024 verabschiedet. In der Mitteilung wurden keine Barbeträge, Preisbedingungen oder Pro-Forma-Dilutionsmetriken erwähnt.
Intellia Therapeutics (NASDAQ:NTLA) أعلنت في 1 أكتوبر 2025 عن منح أسهم حوافز إلى ستة موظفين جدد بموجب خطة الحافز لعام 2024، وتبلغ إجمالي المنح 65,200 RSU من الأسهم العادية، وتكتسب على ثلاث مراحل بالتساوي في 1 أكتوبر 2026، 2027 و2028، رهناً باستمرار الخدمة. تم منح الجوائز خارج الخطط المعتمدة من المساهمين في Intellia ووافقت عليها لجنة التعويضات كمحفز مهم للتوظيف وفقاً لـقاعدة إدراج ناسداك 5635(c)(4). اعتمد مجلس الإدارة خطة الحافز لعام 2024 في يونيو 2024. لم يتضمن البيان أية مبالغ نقدية أو شروط سعر أو مقاييس التخفيف على شكل pro forma للأسهم.
Intellia Therapeutics (NASDAQ:NTLA) 于 2025年10月1日 就其 2024 Inducement Plan 向六名新员工授予诱导性股票奖励，总计 65,200 RSU 普通股，分三期归属：在 2026年10月1日、2027年 和 2028年 各占三分之一，前提是持续任职。该等奖励在 Intellia 的股东批准计划之外授予，且经薪酬委员会按 纳斯达克上市规则 5635(c)(4) 批准为就业的重要诱因。2024 Inducement Plan 于 2024年6月 由董事会通过。公告中未包含现金金额、定价条款或摊薄的临时股数指标。
- None.
- None.
CAMBRIDGE, Mass., Oct. 03, 2025 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, today announced that on October 1, 2025, it awarded inducement grants to six new employees under Intellia’s 2024 Inducement Plan as a material inducement to employment.
The inducement grants consisted of time-based restricted stock units (“RSUs”) for an aggregate of 65,200 shares of Intellia’s common stock, with one-third of such RSUs vesting on October 1, 2026, 2027 and 2028.
All equity vesting is subject to each employee’s continued service as an employee of, or other service provider to, Intellia through the applicable vesting dates.
All of the above-described awards were granted outside of Intellia’s stockholder-approved equity incentive plans pursuant to Intellia’s 2024 Inducement Plan, which was adopted by the board of directors in June 2024. These awards were approved by Intellia’s compensation committee as a material inducement to entering into employment with Intellia in accordance with Nasdaq Listing Rule 5635(c)(4).
About Intellia Therapeutics
Intellia Therapeutics, Inc. (NASDAQ:NTLA) is a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies. Since its inception, Intellia has focused on leveraging gene editing technology to develop novel, first-in-class medicines that address important unmet medical needs and advance the treatment paradigm for patients. Intellia’s deep scientific, technical and clinical development experience, along with its people, is helping set the standard for a new class of medicine. To harness the full potential of gene editing, Intellia continues to expand the capabilities of its CRISPR-based platform with novel editing and delivery technologies. Learn more at intelliatx.com and follow us @intelliatx.
Intellia Contacts:
Investors:
Jason Fredette
Vice President, Investor Relations and Corporate Communications
jason.fredette@intelliatx.com
Media:
Matt Crenson
Ten Bridge Communications
media@intelliatx.com
mcrenson@tenbridgecommunications.com
FAQ
What did Intellia (NTLA) announce on October 1, 2025 regarding employee equity?
What is the vesting schedule for the NTLA inducement RSUs granted October 1, 2025?
Why were the NTLA awards granted outside existing equity plans?
Who approved the inducement awards for Intellia (NTLA)?
When was Intellia’s 2024 Inducement Plan adopted?
Did the press release disclose dilution or financial impact of the NTLA RSU grants?
